We are live on ! Find out more

argenx

ARGX

Market cap $53.4B

Positive

Neutral

Negative

Sentiment 3-Months

Positive 39.3%

Neutral 50%

Negative 10.7%

Zacks Investment Research

Are Medical Stocks Lagging Argenx (ARGX) This Year?

Here is how argenex SE (ARGX) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Argenx (ARGX) This Year?

Zacks Investment Research

FTRE or ARGX: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Fortrea Holdings Inc. (FTRE) and argenex SE (ARGX). But which of these two stocks offers value investors a better bang for their buck right now?

FTRE or ARGX: Which Is the Better Value Stock Right Now?

Investors Business Daily

This Profitable Autoimmune Biotech Trades Near A High And A Buy Point

This profitable Netherlands-based biotech name has produced triple-digit quarterly earnings growth.

This Profitable Autoimmune Biotech Trades Near A High And A Buy Point

Investors Business Daily

Argenx, Stock Of The Day, Eyes Buy Point Amid Triple-Digit Growth

Wells Fargo on Wednesday named the biotech stock a top Q3 tactical pick. An important catalyst looms for Argenx stock.

Argenx, Stock Of The Day, Eyes Buy Point Amid Triple-Digit Growth

Argenx Analyst Is Bullish Despite Changes To Phase 3 Myositis Study

Argenx SE (NASDAQ:ARGX) stock has faced pressure after the company disclosed changes to the analysis plan for its ongoing Phase 3 Vyvgart study in myositis.

Argenx Analyst Is Bullish Despite Changes To Phase 3 Myositis Study

Investors Business Daily

Can Argenx Retake Its Record High — And A Buy Point — On A New Vyvgart Strategy?

Argenx stock reversed course Wednesday, bumping above its 21-day line, as investors digested its myositis-focused R&D Day.

Can Argenx Retake Its Record High — And A Buy Point — On A New Vyvgart Strategy?

argenx SE (ARGX) Discusses R&D Spotlight on Advancing FcRn Leadership in Autoimmune Myositis Transcript

argenx SE (ARGX) Discusses R&D Spotlight on Advancing FcRn Leadership in Autoimmune Myositis Transcript

argenx SE (ARGX) Discusses R&D Spotlight on Advancing FcRn Leadership in Autoimmune Myositis Transcript

argenx Eyes More VYVGART Growth as Pipeline Catalysts Near

Executives at argenex NASDAQ: ARGX told investors at a Goldman Sachs healthcare event that they continue to see meaningful growth opportunities for VYVGART across myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, while also pointing to a busy slate of pipeline readouts in the second half of the year.

argenx Eyes More VYVGART Growth as Pipeline Catalysts Near

Investors Business Daily

Sanofi, An Argenx Rival, Bites The Dust — But A Third Biotech Took The Biggest Hit

Sanofi scrapped a final-phase study Wednesday of an experimental CIDP treatment. The stock tumbled in response.

Sanofi, An Argenx Rival, Bites The Dust — But A Third Biotech Took The Biggest Hit

Zacks Investment Research

ARGX Shares Gain Nearly 9% in a Month: Here's What You Need to Know

argenx stock rises nearly 9% in a month after the FDA expands Vyvgart's gMG label, opening treatment to adult patients regardless of antibody status.

ARGX Shares Gain Nearly 9% in a Month: Here's What You Need to Know

See News Rankings